Drug Trial Radar · NCT06807437
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
274
Planned (sponsor's estimate)
Start
May 9, 2025
Primary completion
Apr 1, 2029
Study completion Apr 1, 2029
Sponsor
- Lead sponsor
- SWOG Cancer Research NetworkResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Feb 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of somatostatin analog similar to somatostatin (a hormone made by the body), and is used to treat certain types of gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome. It may help stop the body from making extra amounts of certain hormones, including growth hormone, insulin, glucagon, and hormones that affect digestion. It may also help keep certain types of tumor cells from growing. Patients with pancreatic cancer or pancreatic lesions may undergo surgery to remove parts of the pancreas, also called a distal pancreatectomy. Patients may experience complications after surgery, including pancreatic fistulas. A pancreatic fistula occurs when there is a small leak from the pancreas, causing fluids to collect. This can often lead to infection and other problems. Giving lanreotide before undergoing distal pancreatectomy may be more effective than surgery alone in preventing the development of a pancreatic fistula in patients with pancreatic cancer or a pancreatic lesion that could become cancerous.
Conditions
- Pancreatic Carcinoma
- Pancreatic Neoplasm
Interventions
Biospecimen CollectionProcedure
Undergo blood sample and pancreas fluid collection
Distal PancreatectomyProcedure
Undergo distal pancreatectomy
LanreotideDrug
Given SC
Questionnaire AdministrationOther
Ancillary studies
SalineOther
Given SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of postoperative pancreatic fistula (POPF)Time frame: Up to 60 days after distal pancreatectomy
Locations
118 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama · Suspended
Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis
Daphne, Alabama · Suspended
Thomas Hospital
Fairhope, Alabama · Suspended
Mobile Infirmary Medical Center
Mobile, Alabama · Suspended
Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland
Saraland, Alabama · Suspended
Banner MD Anderson Cancer Center
Gilbert, Arizona · Suspended
City of Hope Comprehensive Cancer Center
Duarte, California · Suspended
UC San Diego Moores Cancer Center
La Jolla, California · Recruiting
Veterans Affairs Loma Linda Healthcare System
Loma Linda, California · Suspended
USC / Norris Comprehensive Cancer Center
Los Angeles, California · Suspended
UC San Diego Medical Center - Hillcrest
San Diego, California · Suspended
Helen F Graham Cancer Center
Newark, Delaware · Suspended
Medical Oncology Hematology Consultants PA
Newark, Delaware · Suspended
Christiana Care Health System-Christiana Hospital
Newark, Delaware · Suspended
Christiana Care Health System-Wilmington Hospital
Wilmington, Delaware · Suspended
Moffitt Cancer Center at SouthShore
Ruskin, Florida · Suspended
Moffitt Cancer Center-International Plaza
Tampa, Florida · Suspended
Moffitt Cancer Center - McKinley Campus
Tampa, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Suspended
Moffitt Cancer Center at Wesley Chapel
Wesley Chapel, Florida · Suspended
Grady Health System
Atlanta, Georgia · Suspended
Emory University Hospital Midtown
Atlanta, Georgia · Suspended
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia · Suspended
Emory Saint Joseph's Hospital
Atlanta, Georgia · Suspended
Emory Johns Creek Hospital
Johns Creek, Georgia · Suspended
Northwestern University
Chicago, Illinois · Recruiting
University of Illinois
Chicago, Illinois · Recruiting
Northwestern Medicine Cancer Center Delnor
Geneva, Illinois · Suspended
Northwestern Medicine Oak Brook
Oak Brook, Illinois · Suspended
Northwestern Medicine Orland Park
Orland Park, Illinois · Suspended
Northwestern Medicine Cancer Center Warrenville
Warrenville, Illinois · Suspended
Indiana University/Melvin and Bren Simon Cancer Center
Indianapolis, Indiana · Suspended
University of Kentucky/Markey Cancer Center
Lexington, Kentucky · Recruiting
University Medical Center New Orleans
New Orleans, Louisiana · Suspended
Christiana Care - Union Hospital
Elkton, Maryland · Suspended
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan · Suspended
Bronson Battle Creek
Battle Creek, Michigan · Suspended
Corewell Health Grand Rapids Hospitals - Butterworth Hospital
Grand Rapids, Michigan · Suspended
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
Grand Rapids, Michigan · Suspended
Trinity Health Grand Rapids Hospital
Grand Rapids, Michigan · Suspended
Showing 40 of 118 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.